Therapy-related MDS/AML is an increasingly recognized, often fatal late complication after prolonged ...
On May 21, 2024, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) published a warning letter issued to Akan Biosciences, Inc. (Akan) for ...
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, ...
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) There is no consensus on the ...
The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...
The first fixed-dose combination involving Novartis’first-in-class oral renin inhibitor, Tekturna with hydrochlorothiazide (HCT)was approved in the USin January 2008. A single-tablet combination with ...
Bench-scale results demonstrate HCT reduced wax content and produced stable, lighter crude—extending a proven platform from ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results